BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29635268)

  • 1. Comparison table: some systemic fluoroquinolones.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e57-e58. PubMed ID: 29635268
    [No Abstract]   [Full Text] [Related]  

  • 2. Delafloxacin (Baxdela)--a new fluoroquinolone antibiotic.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):49-51. PubMed ID: 29635263
    [No Abstract]   [Full Text] [Related]  

  • 3. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Kaul G; Kapoor E; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Nov; 54(11):657-666. PubMed ID: 30539165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial drugs for community-acquired pneumonia.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):10-14. PubMed ID: 33512346
    [No Abstract]   [Full Text] [Related]  

  • 6. Delafloxacin: First Global Approval.
    Markham A
    Drugs; 2017 Sep; 77(13):1481-1486. PubMed ID: 28748399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Systemic and Topical Fluoroquinolones.
    Jackson MA; Schutze GE;
    Pediatrics; 2016 Nov; 138(5):. PubMed ID: 27940800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [15-year experience of moxifloxacin in the treatment of patients with bacterial rhinosinusitis].
    Ovchinnikov AY; Edzhe MA; Miroshnichenko NA; Hon EM; Korostelev SA
    Vestn Otorinolaringol; 2015; 80(3):75-79. PubMed ID: 26331163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA and the safe and appropriate antibiotic use of fluoroquinolones.
    Tillotson GS
    Lancet Infect Dis; 2016 Mar; 16(3):e11-2. PubMed ID: 26973315
    [No Abstract]   [Full Text] [Related]  

  • 13. Plazomicin (Zemdri) - a new aminoglycoside antibiotic.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):180-182. PubMed ID: 30681656
    [No Abstract]   [Full Text] [Related]  

  • 14. In brief: More fluoroquinolone warnings.
    Med Lett Drugs Ther; 2018 Aug; 60(1553):136. PubMed ID: 30133426
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical review of delafloxacin: a novel anionic fluoroquinolone.
    Mogle BT; Steele JM; Thomas SJ; Bohan KH; Kufel WD
    J Antimicrob Chemother; 2018 Jun; 73(6):1439-1451. PubMed ID: 29425340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections.
    Chu Y; Qu J; Qu LY; Luo YF; Jiang MY
    Drug Res (Stuttg); 2015 Dec; 65(12):650-7. PubMed ID: 26070015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Corey GR; McKinnell JA; Rybak MJ
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S191-S192. PubMed ID: 30957163
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.).
    Chidiac C;
    Med Mal Infect; 2015 Sep; 45(9):348-73. PubMed ID: 26432627
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of fluoroquinolone use to avoid microbial resistance in clinical practice.
    Peterson LR
    Postgrad Med; 2001 Feb; 109(2 Suppl):51-9. PubMed ID: 19667558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.